Table 3. Summary of NS5B polymerase region resistance-associated variants by genotype.
| Residue | L159 | S282 | C316 | V321 |
|---|---|---|---|---|
| Genotype | ||||
| 1a (n = 10) | ||||
| 1b (n = 69) | C316N (64) | |||
| 2a (n = 4) | ||||
| 3a (n = 39) | C316N (1) | V321F (1) | ||
| 3b (n = 25) | C316W (1) | |||
| 6a (n = 201) | C316N (5) | |||
| 6n (n = 2) | ||||
Variants in bold lettering have been shown to have resistance to NS3 protease inhibitors in vitro and in vivo; only these variants were included in calculation of RAV prevalence for each genotype
Variants without bold lettering are present at residues implicated in resistance, but amino acid change not known to confer resistance